NCT01034202 - Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx® | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Growth Hormone DisorderHealthy

Interventions

DRUG

NNC126-0083

One of five dose levels administered subcutaneously (under the skin)

DRUG

Norditropin® SimpleXx®

One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)

DRUG

placebo

Placebo comparator

DRUG

NNC126-0083

One of three dose levels administered subcutaneously (under the skin)

DRUG

Norditropin® SimpleXx®

One of two dose levels, followed by placebo, administered subcutaneously (under the skin)

Trial Locations (1)

Novo Nordisk Investigational Site, Hvidovre